Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5501247 | 1.00 | MEN1 (0.58) | MEN1KMT2APTGDR2 | |
| SCHEMBL4127941 | 1.00 | MEN1 (0.58) | MEN1KMT2APTGDR2 | |
| SCHEMBL4116661 | 0.85 | PTGDR2 (0.65) | MEN1KMT2APTGDR2 | |
| SCHEMBL4123897 | 0.85 | PTGDR2 (0.58) | MEN1KMT2APTGDR2 | |
| SCHEMBL5315752 | 0.85 | MEN1 (0.56) | MEN1KMT2APTGDR2 | |
| SCHEMBL5376563 | 0.85 | MEN1 (0.56) | MEN1KMT2APTGDR2 | |
| SCHEMBL6070868 | 0.85 | MEN1 (0.56) | MEN1KMT2APTGDR2 | |
| SCHEMBL6071132 | 0.85 | MEN1 (0.56) | MEN1KMT2APTGDR2 | |
| SCHEMBL5497430 | 0.85 | PTGDR2 (0.65) | MEN1KMT2APTGDR2 | |
| SCHEMBL6070865 | 0.85 | MEN1 (0.56) | MEN1KMT2APTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | MEN1 4611/4885KMT2A 4216/4885PTGDR2 1/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | MEN1 4793/4885KMT2A 4382/4885PTGDR2 1/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | MEN1 4611/4885KMT2A 4216/4885PTGDR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.